Remote, computerised cognitive assessment for breast cancer- and treatment-related cognitive dysfunction: Psychometric characteristics of the cogsuite neurocognitive battery Journal Article

   

Authors:	Root, J. C.; Gaynor, A. M.; Ahsan, A.; Jung, D.; Schofield, E.; Ryan, E.; Li, Y.; Ahles, T. A.
Article Title:	Remote, computerised cognitive assessment for breast cancer- and treatment-related cognitive dysfunction: Psychometric characteristics of the cogsuite neurocognitive battery
Abstract:	OBJECTIVE: Cancer-related cognitive dysfunction (CRCD) is a significant concern for breast cancer survivors. The Cogsuite battery was developed to improve sensitivity to CRCD with the use of cognitive experimental measures, clarify specific cognitive processes impacted and to be capable of being administered either in-office or remotely. METHODS: In sum, 357 breast cancer survivors and non-cancer controls completed the Cogsuite Battery in-office (n = 76) or remotely (n = 281). Measure validity, sensitivity to demographic factors, correlations with standard neuropsychological measures and intercorrelations of Cogsuite variables were assessed. Test-retest reliability was evaluated in-office (n = 24) and remotely (n = 80). RESULTS: Test-retest reliability for most variables assessed was adequate to strong. Internal validity, as indicated by the confirmation of expected condition effects within each measure, was established for all measures. Assessment of external validity found age, but not education, was a significant predictor in the majority of measures. Assessment of criterion validity found that Cogsuite variables were correlated with standard measures in psychomotor speed, working memory and executive function, but not associated with self-reported cognition or mood. CONCLUSIONS: Cogsuite is reliable and valid, and is sensitive to the effects of increasing age on cognition. The addition of the Cogsuite battery to standard assessment may improve sensitivity to CRCD and identify underlying processes that may be affected. Remote use of the Cogsuite battery in appropriate settings will lessen the burden for providers, researchers and survivors in research and clinical contexts. © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.
Keywords:	reproducibility; reproducibility of results; breast cancer; breast neoplasms; breast tumor; survivorship; neuropsychological tests; cognition; cognitive defect; neuropsychological assessment; psychometrics; psychometry; complication; cognitive dysfunction; cognitive impairment; humans; human; female; cancer-related cognitive dysfunction
Journal Title:	Archives of Clinical Neuropsychology
Volume:	38
Issue:	5
ISSN:	0887-6177
Publisher:	Oxford University Press
Date Published:	2023-08-01
Start Page:	699
End Page:	713
Language:	English
DOI:	10.1093/arclin/acac111
PUBMED:	36655820
PROVIDER:	scopus
PMCID:	PMC10369363
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165733615&doi=10.1093%2farclin%2facac111&partnerID=40&md5=67faecf96a81d4672254ba404c5bd493
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding author is MSK author: J.C. Root -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/208678